Association of prion protein expression with pancreatic adenocarcinoma survival in the SEER residual tissue repository.
Association of prion protein expression with pancreatic adenocarcinoma survival in the SEER residual tissue repository.
复制标题
DOI：
10.3233/cbm-2012-0256
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Xin W
中科院分区：
文献类型：
--
作者：
Sy MS;Altekruse SF;Li C;Lynch CF;Goodman MT;Hernandez BY;Zhou L;Saber MS;Hewitt SM;Xin W
胰腺导管腺癌（Pancreatic ductal adencarcinoma， PDAC）是癌症死亡的重要原因，目前尚无明确的预后生物标志物。据报道，朊病毒（PrP）的表达是一系列高加索PDAC病例预后不良的标志。我们确定了PrP在基于种族和地理不同人群的PDAC病例系列中的预后价值。在三个癌症登记处的142例PDAC病例中检测了PrP表达。病例包括71名高加索人，54名亚洲/太平洋岛民和17名黑人，诊断于1983-2000年，随访至2008年。在调整病例属性后，计算PrP表达与生存率相关性的风险比（HR）和95%置信区间（CIs）。108例PDAC合并PrP+肿瘤（中位生存期为5个月）的死亡风险比34例合并PrP -肿瘤（中位生存期为20个月）的死亡风险高出约4倍（HR=3.8; 95% CI: 2.2, 6.5）。在51例切除的患者中，17例PrP−肿瘤患者的局部PDAC中位生存期为74个月，34例PrP+肿瘤患者的中位生存期为14个月（HR=6.7; 95% CI: 2.6, 17.4）。6例存活病例均为PrP−阴性肿瘤（中位生存期为10年）。PrP可能有潜力作为PDAC患者管理的预后生物标志物。
Pancreatic ductal adenocarcinoma (PDAC) is an important cause of cancer death with no clear prognostic biomarker. Expression of prion (PrP) has been reported to be a marker of poor prognosis in a series of Caucasian PDAC cases. We determined the prognostic value of PrP in a racially and geographically diverse population-based series of PDAC cases. PrP expression was examined in 142 PDAC cases from three cancer registries. Cases included 71 Caucasian, 54 Asian/Pacific Islanders and 17 Blacks diagnosed from 1983–2000, and followed through 2008. Hazard ratios (HR) and 95% confidence intervals (CIs) for the association of PrP expression with survival were computed after adjustment for case attributes. The risk of death was about four times higher (HR=3.8; 95% CI: 2.2, 6.5) among 108 PDAC cases with PrP+ tumors (median survival 5 months) compared to the 34 cases with PrP− tumors (median survival 20 months). Of 51 cases with resected, localized PDAC median survival was 74 months for 17 cases with PrP− tumors versus 14 months for 34 cases with PrP+ tumors (HR=6.7; 95% CI: 2.6, 17.4). All 6 surviving cases had PrP− negative tumors (median survival, >10 years). PrP may have potential as a prognostic biomarker in PDAC patient management.